In rabbits and monkeys, bevacizumab has been detected in fellow eyes after intravitreal injection, but not ranibizumab13(Averyet al14). injected vision. Hence, I reduced the injected dose of bevacizumab down by 200-fold to 6.25 g and was still able to see an effect on leakage of neovascularisation in the injected eye.1Although many fellow eye cases have now been reported, and I have observed it with ranibizumab, aflibercept and bevacizumab, most clinicians have not seen fellow eye effects and discount the plausibility that they occur.23 Other evidence of systemic effects includes numerous reports of decreased systemic vascular endothelial growth factor (VEGF) levels following intravitreal anti-VEGF injections. Matsuyamaet alreported a marked reduction in plasma VEGF levels 1 day, 1 week and 1 month after bevacizumab injection in patients with severe PDR, most of whom experienced rubeosis.4Carneiroet alcompared the effects of intravitreal bevacizumab and ranibizumab on plasma VEGF in a prospective series of age-related macular Phenoxodiol degeneration (AMD) patients and found that the VEGF levels were much lower in bevacizumab Phenoxodiol than ranibizumab patients.5Zehetneret alfound reduced plasma VEGF following injections of bevacizumab, but not ranibizumab or pegaptanib at 1 week and 1 month after treatment of diabetic macular oedema.6IVAN, the largest study to date to measure serum VEGF levels in AMD, reported a reduction of 69% for bevacizumab and 20% for ranibizumab at 1 year, and a reduction of 78% for bevacizumab and 28% for ranibizumab at 2 years.78In a small prospective study, we recently reported reduced plasma VEGF levels following bevacizumab and aflibercept injections, but with minimal reduction following ranibizumab injections (Averyet al9). The effect was most prominent for aflibercept, where a dramatic reduction was noted 3 h after the first injection and persisted at 1, 3 and 7 days. The effect of bevacizumab was less dramatic after the first dose, but after the third monthly dose, systemic accumulation of bevacizumab was noted, and the reduction in VEGF was comparable to that of aflibercept. In this study, RAD50 the concentration of bevacizumab after the third dose exceeded the half maximal inhibitory concentration (IC50) for VEGF, and coincided with the more dramatic reduction in plasma VEGF levels. The concentration of aflibercept after both the first and third doses exceeded the IC50, and corresponded to a marked reduction in plasma VEGF levels. Many authors have measured systemic VEGF levels given the commercial availability of antibodies to VEGF; however, correlation to anti-VEGF drug levels is less generally reported Phenoxodiol because it is more difficult to obtain antibodies to these brokers. Nevertheless, the measurement of VEGF levels in the bloodstream is complex, and although different authors have reported comparable relative results, Phenoxodiol the complete VEGF concentration varies dramatically between studies. One obvious reason for this difference is the plateletwhich contains large concentrations of VEGF. IVAN, which measured serum VEGF, reported very high VEGF levels, in part because the measurement included VEGF released from platelets.7Even plasma levels of VEGF vary between studies, in part because different anticoagulants are better than others for preventing platelet activation.10Despite the variation in absolute VEGF levels between studies, the recurrent obtaining is that bevacizumab lowers systemic VEGF levels much more than ranibizumab.56789The most probable reason for this finding relates to the systemic half-life of the drugs. Bevacizumab and aflibercept contain an Fc fragment that binds an endothelial cell receptor and is recycledthereby prolonging systemic half-life. Ranibizumab, on the other hand, lacks the Fc fragment and has a markedly shorter intrinsic systemic half-life.11In our recent human study, we measured the systemic exposure (AUC) after the third monthly intravitreal injection to be 13-fold greater for aflibercept than ranibizumab and 70-fold.